Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo.

Imran HowellDaniel J BrattonGareth HynesSteven W YanceyLiam G HeaneyIan D PavordRahul Shrimanker

Published in: ERJ open research (2024)

Asthma exacerbations in people treated with mepolizumab result in less peak expiratory flow reduction than placebo but similar symptom scores. Symptoms recover slower, indicating these exacerbations may be less prednisolone responsive. https://bit.ly/3xQsFRB.

Keyphrases

chronic obstructive pulmonary disease
lung function
cystic fibrosis
double blind
phase iii
early onset
cancer therapy
clinical trial
placebo controlled
mechanical ventilation
patient reported
study protocol
newly diagnosed